Data / Form D filings / Oncothyreon Inc.
Oncothyreon Inc.: Form D filings
Oncothyreon Inc., a biotechnology company in Seattle, WA, filed 4 Form D notices with the SEC between 2010 and 2014. The latest, on August 15, 2014, reports $22.9 million sold of a $22.9 million offering to 5 investors.
Find out what Oncothyreon Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 2601 FOURTH AVENUE, SUITE 500, Seattle, WA, 98121
- Phone
- (206) 801-2100
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1412067
The full lists. Form D filings in Washington: 1,095 rows, $54.75, or the new rows each week for $19 a month. Form D filings in Biotechnology: 1,568 rows, $78.40, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, year incorporated, street, city, state and 5 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Aug 15, 2014 | New notice | $22,861,428 | $22,861,428 | $0 | 5 | Aug 8, 2014 | sec.gov |
| Feb 17, 2011 | New notice | Indefinite | $150,000 | Indefinite | 1 | Feb 8, 2011 | sec.gov |
| Oct 6, 2010 | New notice | $28,342,348 | $14,850,045 | $13,492,303 | 17 | Sep 28, 2010 | sec.gov |
| Jul 15, 2010 | New notice | $20,200,000 | $200,000 | $20,000,000 | 1 | Jul 6, 2010 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Scott L. Peterson | Executive Officer | |
| Gary L. Christianson | Executive Officer | |
| Richard L. Jackson | Director | |
| Ted W. Love | Director | |
| Diana L. Hausman | Executive Officer | |
| Robert L. Kirkman | Executive Officer, Director | |
| Julia L. Eastland | Executive Officer | |
| Daniel W. Spiegelman | Director | |
| W. Vickery Stoughton | Director | |
| Jay L. Venkatesan | Executive Officer | |
| Christopher L. Henney | Director |
Other biotechnology companies in Washington that filed recently
- Key Proteo, Inc. $2.3 million · Oct 23, 2026
- Inmedix, Inc. $4 million · Oct 22, 2026
- Q-Immune, Inc. $25,000 · Sep 28, 2026
- Hexamer Therapeutics, Inc $500,000 · Sep 15, 2026
- MalarVx, Inc. $125,000 · Aug 25, 2026
- Strella Biotechnology, Inc. $1.8 million · Aug 14, 2026
Every Form D from the week of Aug 11, 2014 · All recent filings in Washington · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Oncothyreon Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.